Theriva Biologics Responds to Unusual Market Activity, Attributes No Material Business Development or Reason for Trading Action
ByAinvest
Friday, Oct 24, 2025 2:34 pm ET1min read
TOVX--
Theriva Biologics, a clinical-stage company developing therapeutics for cancer and related diseases, has announced unusual trading activity in its common stock on the NYSE American. The company has made inquiries and does not believe corrective actions are necessary. The unusual market action may be attributed to the company's recent announcement of expanded data from its VIRAGE trial investigating VCN-01 at ESMO 2025 Annual Congress.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet